The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial

Schizophrenia Research

Volumn 166, Issue 1-3, 2015, Pages 194-200

  Constantine, Robert J ^a   Andel, Ross ^a   McPherson, Marie ^a   Tandon, Rajiv ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; Clinical trial; Monotherapy; Polypharmacy; Randomized; Schizophrenia; Switch; Treatment

Indexed keywords

CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HEMOGLOBIN A1C; OLANZAPINE; TRIACYLGLYCEROL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; FOLLOW UP; PATIENT COMPLIANCE; POLYPHARMACY; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYPHARMACY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84955200894     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.05.038     Document Type: Article

References (44)

1. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders-4th Edition Text Revision (DSM-IV-TR). American Psychiatric Association, Washington D.C.
2. Astrachan, B.M., Harrow, M., Adler, D., Brauer, L., Schwartz, A., Schwartz, C., et al., 1972. A checklist for the diagnosis of schizophrenia. Br. J. Psychiatry 121, 529-539.
3. Barnes, T., 1989. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676.
4. Barnes, T.R.E., Paton, C., 2011. Antipsychotic polypharmacy in schizophrenia. CNS Drugs 25, 383-399.
5. Brissos, S., Veguilla, M.R., Taylor, D., Balanza-Martinez, V., 2014. The role of long-acting antipsychotics in schizophrenia: a critical appraisal. Ther. Adv. Psychopharmacol. 4, 198-219.
6. Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., et al., 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36, 71-93.
7. Constantine, R., Andel, R., Tandon, R., 2010. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid. Community Ment. Health J. 46, 523-530.
8. Constantine, R., McPherson, M.A., Jones, M.E., Tandon, R., Becker, E.R., 2013. Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP). Community Ment. Health J. 49, 33-44.
9. Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S., 2009. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 35, 443-457.
10. Covell, N.H., McEvoy, J.P., Schooler, N.R., Stroup, T.S., Jackson, C.T., Rojas, I.A., Essock, S.M., 2012. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J. Clin. Psychiatry 73, 669-675.
11. Essock, S.M., Covell, N.H., Davis, S.M., Stroup, T.S., Rosenheck, R.A., Lieberman, J.A., 2006. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 163, 2090-2095.
12. Essock, S.M., Schooler, N.R., Stroup, T.S., McEvoy, J.P., Rojas, I., Jackson, C., et al., 2011. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry 168, 702-708.
13. Fleischhacker, W.W., Uchida, H., 2012. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2, 1-11.
14. Florida Drug TherapyManagement Program for Behavioral Health, 2011. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. medicaidmentalhealth.org.
15. Gallego, J.A., Nielsen, J., de Hert, M., Kane, J.M., Correll, C.U., 2012. Safety and tolerability of antipsychotic polypharmacy. Expert Opin. Drug Saf. 11, 527-542.
16. Gardner, D.M., Murphy, A.L., O'Donnell, H., Centorrino, F., Baldessarini, R.J., 2010. International consensus study of antipsychotic dosing. Am. J. Psychiatry 167, 686-693.
17. Gilmer, T.P., Dolder, C.R., Folsom, D.P., Mastin, W., Jeste, D.V., 2007. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego county. 1999-2004. Psychiatr. Serv. 58, 1007-1010.
18. Godleski, L.S., Kerler, R., Barber, J.W., Glick, J.I., Kellog, E., Vieweg, W.V.R., et al., 1989. Multiple versus single antipsychotic drug treatment in chronic psychosis. J. Nerv. Ment. Dis. 177, 686-689.
19. Goren, J.L., Meterko, M., Williams, S., Young, G.J., Baker, E., Chou, C.-H., et al., 2013. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr. Serv. 64, 527-533.
20. Guy, W., 1976. The ECDEU assessment manual for psychopharmacology-Revised. U.S. Department of Health, Education, and Welfare, Alcohol, Drug Abuse, Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD.
21. Hatta, K., Otachi, T., Fujita, K., Morikawa, F., Ito, S., Tomiyama, H., et al., 2014. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophr. Res. 158, 213-222.
22. Hori, H., Yoshimura, R., Katsuki, A., Sugita, A.-I., Atake, K., Nakamura, J., 2013. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J. Psychiatr. Res. 47, 1843-1848.
23. Kales, H.C., DeQuardo, J.R., Tandon, R., 1999. Combined electroconvulsive therapy and clozapine in treatment-refractory schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 547-556.
24. Katona, L., Czobor, P., Bitter, I., 2014. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nation-wide study in Hungary. Schizophr. Res. 152, 246-254.
25. Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
26. Li, Q., Xiang, Y.-T., Su, Y.-A., Shu, L., Yu, X., Chiu, H.F.K., et al., 2015. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life. Findings of the third national survey on use of psychotropic medications in China. Aust. N. Z. J. Psychiatry 49, 129-136.
27. Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D., Schabenberger, O., 2006. SAS for mixed models. Second edition. SAS Institute Inc., Cary, NC.
28. Marder, S.R., Essock, S.M., Miller, A.L., et al., 2004. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161, 1334-1349.
29. Mojtabai, R., Olfson, M., 2010. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 67, 26-36.
30. Morisky, D.E., Green, L.W., Levine, D.M., 1986. Concurrent and predictive validity of a selfreported measure of medication adherence. Med. Care 24, 67-74.
31. National Collaborating Centre for Mental Health, 2009. Schizophrenia, 2009. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). Clinical Guidelinep. 82.
32. Park, S.-C., Lee, M.-S., Kang, S.-G., Lee, S.-H., 2014. Patterns of antipsychotic prescription to aptients with schizophrenia in Korea: results from the Health Insurance Review and Assessment Service-National patient sample. J. Korean Med. Sci. 29, 719-728.
33. Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11-19.
34. Sun, F.F., Stock, E.M., Copeland, L.A., Zeber, J.E., Ahmedani, B.K., Morisette, S.B., 2014. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am. J. Health Syst. Pharm. 71, 728-738.
35. Suzuki, T., Uchida, H., Tanaka, K.F., Nomura, K., Takano, H., Tanabe, A., et al., 2004. Revising polypharmacy to a single antipsychotic regimen for patients with schizophrenia. Int. J. Neuropsychopharmacol. 7, 133-142.
36. Tandon, R., 2011. Antipsychotics in the treatment of schizophrenia. J. Clin. Psychiatry 72, 1-8.
37. Tandon, R., Halbreich, U., 2003. The second-generation antipsychotics: similar efficacy but different neuroendocrine side-effects. Psychoneuroendoc. 28 (Suppl.1), 1-7.
38. Tandon, R., Targum, S.D., Nasrallah, H.A., Ross, R., 2006. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 12, 348-363.
39. Tandon, R., Moller, H.-J., Belmaker, R.H., et al., 2008. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100, 20-38.
40. Tandon, R., Nasrallah, H.A., Keshavan, M.S., 2010. Schizophrenia, "Just the facts" 5. Treatment and prevention. Schizophr. Res. 122, 1-23.
41. Tani, H., Uchida, H., Suzuki, T., Fujii, Y., Mimura, M., 2013. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr. Res. 143, 215-220.
42. Tsutsumi, C., Uchida, H., Suzuki, T., Watanabe, K., Takeuchi, H., Nakajima, S., et al., 2011. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr. Res. 130, 40-46.
43. Velligan, D.I., Carroll, C., Lage, M.J., Fairman, K., 2015. Outcomes of Medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatr. Serv. 2015. http://dx.doi.org/10.1176/appi.ps.201300085.
44. Young, S.L., Taylor, M., Lawrie, S.M., 2015. "First do no harm". A systematic review of the prevalence andmanagement of antipsychotic adverse effects. J. Psychopharmacol. 29, 351.